Lower vitamin D in blood causes Alzheimer's Disease (Mendelian gene analysis)

Circulating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank.

J Alzheimers Dis. 2019 Dec 2. doi: 10.3233/JAD-190713

Wang L1, Qiao Y2, Zhang H3, Zhang Y2, Hua J4, Jin S4, Liu G3,5.

* Many other studies have found Vitamin D to be associated with Alzheimer's Disease * This study found that genes which result in lower blood level of vitamin D are associated with Alzheimer's Disease --- This study appears to ignore the 7 additional genes which can further decrease the amount of Vitamin D actually getting to the brain * Alzheimer’s is associated with all 7 of the genes which restrict vitamin D from getting to tissues – Sept 2018 * 8 genes associated with both Alzheimer’s and lowish Vitamin D – May 2019 * Resveratrol improves health (Vitamin D receptor, etc.) - many studies * Resveratrol INCREASES the Vitamin D getting from the blood to the cells * * *articles are in both Cognition and Vitamin D Receptor categories * articles are in both Cognition and Vitamin D Genes categories --- * Alzheimer’s Disease risk is 1.3X higher if Vitamin D deficient – meta-analysis Nov 2019 * Risk of Dementia and Alzheimer's reduced by higher levels of Vitamin D – meta-analysis Feb 2018 * Risk of Alzheimer's decreases as Vitamin D increases** --- 1. Overview Alzheimer's-Cognition and Vitamin D starts with {include}

📄 Download the PDF from Sci-Hub via VitaminDWiki

Observational studies strongly supported the association of low levels of circulating 25-hydroxyvitamin D (25OHD) and cognitive impairment or dementia in aging populations. However, randomized controlled trials have not shown clear evidence that vitamin D supplementation could improve cognitive outcomes. In fact, some studies reported the association between vitamin D and cognitive impairment based on individuals aged 60 years and over. However, it is still unclear that whether vitamin D levels are causally associated with Alzheimer's disease (AD) risk in individuals aged 60 years and over. Here, we performed a Mendelian randomization (MR) study to investigate the causal association between vitamin D levels and AD using a large-scale vitamin D genome-wide association study (GWAS) dataset and two large-scale AD GWAS datasets from the IGAP and UK Biobank with individuals aged 60 years and over. Our results showed that genetically increased 25OHD levels were significantly associated with reduced AD risk individuals aged 60 years and over. Hence, our findings in combination with previous literature indicate that maintaining adequate vitamin D status in older people especially aged 60 years and over, may contribute to slow down cognitive decline and to forestall AD. Long-term randomized controlled trials are required to test whether vitamin D supplementation may prevent AD in older people especially those aged 60 years and may be recommended as preventive agents.